Recent studies find that the induction of vessel narrowing, hypoxia, and hemorrhagic necrosis in murine mammary tumors by vascular disrupting agents, such as combretastatin A4, is accompanied by elevated tumor levels of the chemokine CXCL12 and tumor cell repopulation [49]. Here, CXCL12 is linked to breast cancer.